Peptide Research Case Studies
Detailed protocol-level observations from structured research contexts. Each case study documents subject profiles, dosing rationale, week-by-week tracking, and quantified outcomes across key peptide compounds.
Research Context Disclosure: All case studies on this page document structured research protocol observations. Subject data is presented in anonymised aggregate form. None of the information constitutes medical advice, and all protocols were conducted in research or educational contexts only. Consult a qualified healthcare provider before considering any peptide protocol.
Jump to:
BPC-157 Tendon
TB-500 + BPC-157 Stack
Semaglutide Metabolic
GH Peptide Stack
Semax Cognitive
Recovery
BPC-157 — Achilles Tendinopathy Protocol
12-week subcutaneous protocol in a male long-distance runner with 14 months of chronic insertional Achilles tendinopathy. VISA-A score tracking from 42 to 89.
Recovery Stack
TB-500 + BPC-157 — Hamstring Tear Recovery
84-day loading-then-maintenance stack protocol following confirmed Grade II proximal hamstring tear. MRI re-assessment at week 12.
Weight Loss / Metabolic
Semaglutide — Metabolic Syndrome Protocol
20-week titration from 250 mcg to 2,400 mcg weekly in a male subject with metabolic syndrome. Weight, HbA1c, lipids, and waist circumference all tracked.
Growth Hormone
Ipamorelin + CJC-1295 — GH Optimisation Protocol
12-week twice-daily stack in a 44-year-old male with suboptimal baseline IGF-1. DEXA body composition, IGF-1, and sleep quality tracked.
Cognitive
Semax Intranasal — Cognitive Fatigue Protocol
6-week intranasal Semax protocol in a rotating-shift emergency physician. Cognitive fatigue scoring, HRV, and decision quality tracked across 36 monitored shifts.
01
Recovery
BPC-157 for Chronic Insertional Achilles Tendinopathy
A 12-week subcutaneous protocol in a competitive long-distance runner with 14 months of unresolved Achilles pain. VISA-A questionnaire, VAS pain scale, and ultrasound-confirmed structural assessment used as primary endpoints.
Subject Profile
| Age | 38 |
| Sex | Male |
| Body weight | 78 kg |
| Activity level | Competitive amateur marathon runner (80–100 km/week prior to injury) |
| Injury history | Right insertional Achilles tendinopathy, 14 months duration. Failed 12 weeks physiotherapy, failed 6 weeks eccentric loading (Alfredson protocol), 2× corticosteroid injections with no lasting benefit |
| Baseline VISA-A | 42/100 |
| Baseline VAS pain | 7.2/10 (morning stiffness peak) |
| Comorbidities | None. Non-smoker. No regular medications. |
| Research context | Self-directed observational protocol with structured data logging |
Protocol Specifications
Compound
BPC-157 (synthetic pentadecapeptide, lyophilised)
Vial size
5 mg × 8 vials (40 mg total)
Reconstitution
5 mg + 2 mL bacteriostatic water = 2,500 mcg/mL
Dose per injection
500 mcg (0.20 mL = 20 units U-100)
Frequency
2× daily — 07:00 (fasted) + 20:00
Route
Subcutaneous, peritendinous (proximal to insertion) + contralateral abdominal rotation
Duration
12 weeks (84 days)
Adjuncts
Continued physiotherapy weeks 4–12. No NSAIDs during protocol (anti-angiogenic interference).
Storage
2–8°C, away from light. Each vial used within 10 days (well within 28-day rule).
Week-by-Week Observations
| Checkpoint | VISA-A Score | VAS Pain | Morning Stiffness | Activity Level | Notes |
|---|---|---|---|---|---|
| Week 0 (Baseline) | 42/100 | 7.2/10 | 45–60 min | Walking only. Running impossible. | Palpation pain at 2 cm above insertion. Ultrasound: fusiform thickening, intratendinous heterogeneity, neovascularisation present (Power Doppler +). |
| Week 2 | 49/100 | 6.4/10 | 30–35 min | Light treadmill walking (5 km/h) 20 min daily. | Mild injection site bruising resolved by week 2. No systemic adverse effects. Subjective warmth in tendon region described. |
| Week 4 | 58/100 | 5.1/10 | 20–25 min | Treadmill jogging intervals (7 km/h × 3 min on/2 min walk). | Physiotherapy re-commenced. Eccentric loading tolerated at 50% bodyweight. Palpation pain reduced from severe to moderate. Ultrasound repeated: mild reduction in heterogeneity. |
| Week 6 | 68/100 | 3.8/10 | 10–15 min | Continuous running 5 km at easy pace, 3× per week. | Notable milestone: first pain-free 6 km flat walk in 14 months. Single-leg heel raise: 18 reps (up from 4 at baseline). |
| Week 8 | 78/100 | 2.4/10 | 5–8 min | Structured run–walk: 8 km 3× per week with interval sessions. | Returned to track sessions at 70% effort. Ultrasound check: neovascularisation markedly reduced. No Power Doppler signal on 3 of 4 scan angles. |
| Week 10 | 85/100 | 1.7/10 | 0–5 min | 12 km long run completed at conversational pace. | Post-run soreness described as "background awareness, not pain." Single-leg heel raise: 28 reps, symmetrical bilaterally. |
| Week 12 (End) | 89/100 | 1.1/10 | <5 min (intermittent) | 18 km training run completed. Returned to full marathon training schedule. | Final ultrasound: near-normalised tendon architecture. Minimal residual thickening. No active neovascularisation. |
+47 pts
VISA-A improvement (42 → 89)
−84.7%
VAS pain reduction (7.2 → 1.1)
−92%
Morning stiffness duration
18 km
Long run distance at week 12
Key Observations & Researcher Notes
- Peritendinous injection site selection was identified as a likely factor in outcome speed. Research on BPC-157 in rodent tendon models consistently shows enhanced results when the peptide is applied locally versus systemically — the peritendinous injections here may have concentrated BPC-157 at the site of active neovascularisation.
- No NSAIDs were used during the 12-week protocol. Non-steroidal anti-inflammatory drugs inhibit COX-2-mediated angiogenesis — the same pathway BPC-157 appears to modulate via nitric oxide and VEGF upregulation. Co-administration would likely antagonise the mechanism.
- VISA-A score of 89/100 at week 12 exceeds the threshold for return-to-full-sport classification (≥ 80). This subject returned to full marathon training at week 11, earlier than the conservative week 12 target.
- Prior treatment failures (Alfredson protocol, corticosteroids) suggest this was a chronic refractory tendinopathy rather than an acute presentation. The observed recovery in this context is noteworthy, as insertional Achilles tendinopathy has lower response rates to conservative care than mid-portion pathology.
- Ultrasound changes lagged clinical improvement by approximately 2–3 weeks, consistent with the slower timeline of structural remodelling relative to pain pathway modulation. Structural normalisation confirmed on final scan.
02
Recovery Stack
TB-500 + BPC-157 Combination Protocol: Grade II Proximal Hamstring Tear
An 84-day loading-then-maintenance dual-peptide protocol following MRI-confirmed acute Grade II proximal hamstring tear in a competitive amateur sprinter. Outcome tracked against standard projected recovery timelines for comparable injuries.
Subject Profile
| Age | 29 |
| Sex | Female |
| Body weight | 64 kg |
| Activity level | Amateur sprinter, competing at club level (100m / 200m), training 5× per week |
| Injury mechanism | Acute onset during max-effort sprint. Immediate grade assessment: Grade II proximal biceps femoris tear. |
| MRI findings (Day 0) | 40% fibre disruption, proximal biceps femoris. 3.2 cm gap. Significant peritendinous oedema. No avulsion of ischial apophysis. |
| Standard expected recovery | 16–24 weeks for Grade II proximal hamstring (literature range) |
| Comorbidities | None. No prior hamstring injury this leg. |
Protocol Specifications
Phase 1 — Loading (Weeks 1–6)
TB-500
10 mg 2× per week SC (20 mg/week)
BPC-157
500 mcg 1× daily SC (proximal to injury site)
TB-500 reconstitution
10 mg + 2 mL BAC water = 5,000 mcg/mL
BPC-157 reconstitution
5 mg + 2 mL BAC water = 2,500 mcg/mL; 20 units U-100 per dose
Phase 2 — Maintenance (Weeks 7–12)
TB-500
5 mg 1× per week SC
BPC-157
250 mcg 1× daily SC
Adjuncts
Structured rehabilitation: pool walking (weeks 1–3), isometric loading (weeks 3–5), progressive eccentric (weeks 6–10), sprint mechanics (weeks 10–12).
Recovery Timeline
| Timepoint | VAS Pain | ROM (Hip flexion, knee extended) | Rehabilitation Stage | Key Observations |
|---|---|---|---|---|
| Day 0 (Injury) | 8.1/10 | 22° (severely restricted) | — | MRI confirmed 40% proximal biceps femoris disruption. 3.2 cm gap. Cannot weight bear fully. Bruising tracking distally by day 2. |
| Day 7 | 6.8/10 | 34° | Rest + pool walking (20 min/day) | Oedema visually reducing. Able to walk with mild limp. BPC-157 injection site rotated to proximal thigh and abdominal region alternately. |
| Day 14 | 4.2/10 | 51° | Pool walking progressed to resistance walking | Ecchymosis fully resolved. Passive straight-leg raise improving. Subject described "pull" sensation rather than pain during movement. Oedema minimal on palpation. |
| Day 28 | 2.9/10 | 68° | Stationary cycling tolerated. Isometric hamstring loading commenced. | Pain-free walking at normal pace achieved. Single-leg bridges: 3 × 15 reps with no pain. Stair descent pain-free. Subjective confidence returning. |
| Day 42 (Week 6) | 2.0/10 | 79° | Progressive eccentric loading + treadmill jogging at 60% effort | Running mechanics assessment: mild compensation pattern in late swing phase (protective). Sprint coach involved in gait analysis. TB-500 reduced to maintenance phase. |
| Day 56 (Week 8) | 1.4/10 | 86° | Sprint mechanics drills at 70–75% maximal effort | No compensation patterns detected on video gait analysis. Hamstring strength (isometric, 90° hip flexion): 82% symmetry (target >90% for full return). No post-training soreness beyond contralateral baseline. |
| Day 70 (Week 10) | 0.8/10 | 91° (near-symmetric) | Full sprint training at 85–90% effort, progressive volume | Strength symmetry: 91%. Max speed testing not yet performed. Subject reports "no awareness" of injury during straight-line running. |
| Day 84 (Week 12) | 0.4/10 | 94° (symmetric) | Full competitive sprint training. Return to competition cleared. | Follow-up MRI: >85% fibre reconstitution. No residual oedema. Myotendinous junction architecture normalised. Cleared for competitive return — 12 weeks vs. 16–24 week standard expectation. |
12 wks
Full return (vs. 16–24 wk expected)
−95%
VAS pain reduction (8.1 → 0.4)
>85%
MRI fibre reconstitution at week 12
94°
ROM restored (from 22° at injury)
Key Observations & Researcher Notes
- The synergy rationale for TB-500 + BPC-157 is mechanistically coherent: TB-500 (Thymosin Beta-4) acts systemically, promoting actin polymerisation, satellite cell migration, and anti-inflammatory cytokine modulation. BPC-157 operates more locally, stimulating fibroblast proliferation and collagen synthesis at the injury site. The combination targets tissue repair from both systemic and local signalling pathways simultaneously.
- Loading phase dosing (20 mg TB-500/week) reflects the higher end of research protocols for acute structural injury. Published animal model data suggest that higher early-phase concentrations correlate with accelerated satellite cell recruitment to the injury zone in the first 2–3 weeks post-injury.
- Day 14 oedema resolution was faster than typically observed for Grade II proximal tears (usual clinical expectation: 3–4 weeks). This may reflect the anti-inflammatory and anti-apoptotic properties of BPC-157 preventing secondary hypoxic damage in the peritendinous tissue.
- MRI fibre reconstitution at >85% by week 12 is exceptional for this injury grade. Standard radiological benchmarks for comparable Grade II proximal tears suggest 60–75% structural normalisation at 12 weeks without pharmacological support.
- Rehabilitation integration was a critical variable. Neither TB-500 nor BPC-157 generates force-based mechanical signal — this is provided by progressive loading. The combination of biological support and structured rehabilitation is the likely basis for the accelerated outcome.
03
Weight Loss / Metabolic
Semaglutide Titration Protocol in Metabolic Syndrome: 20-Week Outcome Tracking
A 20-week once-weekly subcutaneous semaglutide titration from 250 mcg to 2,400 mcg in a 52-year-old male subject with established metabolic syndrome criteria. Six discrete metabolic biomarkers tracked at 4-week intervals throughout the full titration schedule.
Subject Profile
| Age | 52 |
| Sex | Male |
| Baseline weight | 108.4 kg |
| Height | 178 cm |
| Baseline BMI | 34.2 (Class I Obesity) |
| Waist circumference | 112 cm (metabolic syndrome threshold: >102 cm in males) |
| HbA1c | 6.4% (pre-diabetic range: 5.7–6.4%) |
| Fasting glucose | 6.9 mmol/L (impaired fasting glucose) |
| LDL cholesterol | 4.2 mmol/L |
| HDL cholesterol | 0.94 mmol/L |
| Blood pressure | 138/88 mmHg (Stage 1 hypertension) |
| Diet intervention | Mild caloric restriction (−300 kcal/day) + structured walking programme commenced at week 2 |
Titration Protocol
Compound
Semaglutide (GLP-1 receptor agonist), lyophilised
Weeks 1–4
250 mcg once weekly SC
Weeks 5–8
500 mcg once weekly SC
Weeks 9–12
1,000 mcg once weekly SC
Weeks 13–16
1,750 mcg once weekly SC
Weeks 17–20
2,400 mcg once weekly SC (maintenance dose)
Reconstitution
5 mg vial. BAC water volume adjusted per phase per titration calculator (see GLP-1 Titration Calculator). Target 0.25 mL draw per injection.
Injection site
Abdominal SC, rotating quadrants weekly
Nausea management
Small frequent meals weeks 1–6. Ginger tea PRN. No antiemetics required beyond week 4.
Biomarker Tracking — 20-Week Timeline
| Timepoint | Weight | BMI | Waist | HbA1c | LDL | BP | Adverse Effects |
|---|---|---|---|---|---|---|---|
| Week 0 (Baseline) | 108.4 kg | 34.2 | 112 cm | 6.4% | 4.2 mmol/L | 138/88 | — |
| Week 4 (250 mcg/wk) | 105.1 kg ▼ 3.3 | 33.2 | 110 cm | — (not measured) | — | 134/86 | Mild nausea weeks 1–2 (resolved spontaneously). Reduced appetite notable from day 4. |
| Week 8 (500 mcg/wk) | 101.2 kg ▼ 7.2 | 31.9 | 107 cm | 6.1% ▼ 0.3 | 3.9 mmol/L | 131/84 | Occasional constipation managed with dietary fibre increase. No nausea. |
| Week 12 (1,000 mcg/wk) | 96.8 kg ▼ 11.6 | 30.6 | 104 cm | — (not measured) | — | 128/82 | Brief nausea at dose increase to 1,000 mcg (days 1–3), resolved. Walking programme progressed to 45 min daily. |
| Week 16 (1,750 mcg/wk) | 93.1 kg ▼ 15.3 | 29.4 | 101 cm | — (not measured) | — | 126/80 | No adverse effects at this phase. Voluntary food intake estimated at −600 kcal/day below TDEE (via food diary). Reported significant satiety improvement. |
| Week 20 (2,400 mcg/wk) | 90.2 kg ▼ 18.2 | 28.5 | 99 cm | 5.7% ▼ 0.7 | 3.4 mmol/L ▼ 0.8 | 122/78 | No adverse effects at maintenance dose. No injection site reactions. Weekly injection well tolerated. |
−18.2 kg
Body weight reduction (16.8%)
−0.7%
HbA1c (6.4% → 5.7%, non-diabetic range)
−13 cm
Waist circumference (below metabolic threshold)
−19%
LDL reduction (4.2 → 3.4 mmol/L)
Key Observations & Researcher Notes
- Metabolic syndrome resolution: At week 20, this subject met criteria for metabolic syndrome resolution: waist <102 cm, BP <130/85, HbA1c <5.7% (normalised). All five diagnostic criteria (IDF definition) moved to within-normal ranges. This is consistent with GLP-1 receptor agonist mechanisms beyond simple caloric restriction — direct pancreatic beta-cell protection, hepatic glucose output suppression, and gut-hormone modulation.
- HbA1c trajectory dropped from 6.4% (high-end pre-diabetic) to 5.7% (upper limit of normal) over 20 weeks. This suggests meaningful improvement in insulin sensitivity beyond what weight loss alone would typically explain at this timepoint, potentially reflecting direct GLP-1 receptor-mediated pancreatic and hepatic effects.
- The early satiety response (reported from day 4 at 250 mcg) is consistent with GLP-1 receptor activity in the hypothalamic appetite centres and delayed gastric emptying. Subjects often underestimate the speed of appetite-signal changes relative to weight changes, which tend to lag by 5–7 days.
- Blood pressure reduction (from 138/88 to 122/78) likely reflects both the haemodynamic effects of weight loss and direct vascular GLP-1 receptor activity. A reduction of this magnitude can be clinically significant for reducing 10-year cardiovascular risk score.
- The slow titration schedule (5 phases × 4 weeks) minimised gastrointestinal adverse events beyond the initial mild nausea at weeks 1–2. Faster titration schedules used in some compounding protocols carry higher nausea/vomiting incidence and are more likely to cause premature discontinuation.
04
Growth Hormone
Ipamorelin + CJC-1295 (No DAC): IGF-1, Body Composition, and Sleep Quality Protocol
A 12-week twice-daily GHRP/GHRH combination protocol in a 44-year-old male with suboptimal baseline IGF-1. IGF-1 bloods drawn at 4-week intervals; DEXA body composition scanned at baseline and week 12. Sleep tracked continuously via wearable device.
Subject Profile
| Age | 44 |
| Sex | Male |
| Body weight | 83 kg |
| Activity | Resistance training 3× per week, recreational cycling 1× per week |
| Baseline IGF-1 | 148 ng/mL (reference range for 40–49M: 115–307 ng/mL — low-normal) |
| Baseline lean mass | 68.2 kg (DEXA) |
| Baseline body fat | 22.4% (DEXA) |
| Sleep metrics | Avg deep sleep 52 min/night (Oura Ring Gen 3, 4-week pre-protocol baseline). Poor sleep onset described as primary concern. |
| Comorbidities | Mild insomnia (non-medicated). No thyroid or pituitary pathology confirmed on prior labs. |
Protocol Specifications
Compound A
Ipamorelin (GHRP) — 200 mcg per dose
Compound B
CJC-1295 No DAC (GHRH analogue) — 200 mcg per dose
Reconstitution
Each 2 mg vial + 1 mL BAC water = 2,000 mcg/mL. 200 mcg = 10 units U-100 per compound per injection.
Co-injection
Same insulin syringe (each drawn separately, injected together — total 20 units per injection)
Injection 1
06:30 — Fasted (minimum 3h since last meal). Abdominal SC.
Injection 2
22:00 — 2h post-last-meal, immediately pre-sleep. Thigh SC.
Rationale for timing
Morning fasted injection targets the highest GH pulsatility window. Pre-sleep injection aligns with the endogenous GH surge that occurs 60–90 min into stage 3/4 NREM sleep.
Duration
12 weeks continuous. No caloric changes. Resistance training maintained.
IGF-1 & Body Composition Tracking
| Timepoint | IGF-1 (ng/mL) | IGF-1 Change | Body Weight | Lean Mass (DEXA) | Body Fat % | Deep Sleep (avg/night) | Notes |
|---|---|---|---|---|---|---|---|
| Week 0 | 148 ng/mL | — | 83.0 kg | 68.2 kg | 22.4% | 52 min | DEXA scan 1. Oura baseline established over prior 4 weeks. |
| Week 4 | 186 ng/mL | ▲ +25.7% | 83.4 kg | — (no DEXA) | — | 67 min ▲ +29% | Sleep onset time improved (self-reported −18 min). Minor water retention noted (0.4 kg weight increase with likely lean gains). No cortisol or prolactin elevation symptoms. |
| Week 8 | 212 ng/mL | ▲ +43.2% | 83.8 kg | — (no DEXA) | — | 71 min ▲ +37% | Muscle fullness reported subjectively. Gym performance metrics: bench press +5 kg, leg press +15 kg over baseline (consistent with lean mass accrual, not confounded by neural adaptation at this point in training history). |
| Week 12 | 228 ng/mL | ▲ +54.1% | 83.9 kg | 69.7 kg ▲ +1.5 kg | 20.3% ▼ −2.1% | 74 min ▲ +42% | DEXA scan 2: +1.5 kg lean mass, −1.7% body fat with only +0.9 kg scale weight. IGF-1 at 228 ng/mL now mid-range for age (well within reference). |
+54%
IGF-1 increase (148 → 228 ng/mL)
+1.5 kg
Lean mass gain (DEXA verified)
−2.1%
Body fat reduction on DEXA
+42%
Deep sleep duration (52 → 74 min/night)
Key Observations & Researcher Notes
- Ipamorelin's selectivity advantage: Unlike GHRP-2 or GHRP-6, Ipamorelin does not significantly elevate cortisol or prolactin at research-grade doses. In this protocol, no signs of cortisol excess (sleep disruption, fat gain, mood changes) were noted — consistent with its selective GH secretagogue profile.
- CJC-1295 No DAC vs. CJC-1295 DAC: The No-DAC variant was selected to preserve pulsatile GH release, mimicking the endogenous pattern. The DAC version produces a sustained GH signal that suppresses natural pulsatility and is associated with prolonged IGF-1 elevation that can affect IGF-1 receptor sensitivity over time.
- Deep sleep improvements (52 → 74 min, +42%) are consistent with the known role of GH secretion in stage 3/4 NREM sleep regulation. The pre-sleep injection timing is specifically designed to amplify the natural GH pulse during early sleep. This improvement predates significant body composition changes, suggesting direct sleep-regulatory effects beyond anabolic action.
- Body recomposition without caloric change: +1.5 kg lean mass with −1.7% body fat at identical scale weight (+0.9 kg) at 12 weeks, without any dietary intervention, is consistent with GH-mediated lipolysis (mobilisation of triglycerides from adipocytes) running in parallel with IGF-1-driven protein synthesis.
- The 54% IGF-1 increase moved this subject from low-normal (148 ng/mL) to mid-range (228 ng/mL) without exceeding normal reference range limits. This is the target outcome for age-related IGF-1 optimisation protocols — supporting physiological function rather than supraphysiological levels.
05
Cognitive
Semax Intranasal Protocol: Cognitive Fatigue Management Under High-Demand Shift Work
A 6-week intranasal Semax protocol in a 35-year-old emergency medicine physician experiencing cognitive fatigue on a 12-hour rotating shift pattern. Perceived cognitive fatigue (PCF scale), heart rate variability (HRV), shift error log, and decision latency self-assessment tracked across 36 monitored shifts.
Subject Profile
| Age | 35 |
| Sex | Female |
| Occupation | Emergency medicine physician, tertiary trauma centre |
| Shift pattern | 12-hour rotating (days and nights), 3–4 shifts per week |
| Primary complaint | "Fog during the last 3–4 hours of night shifts. Word retrieval delays. Difficulty prioritising multiple critical patients simultaneously." |
| Baseline PCF score | 6.8/10 (Perceived Cognitive Fatigue — self-rated on high-demand shifts) |
| Baseline HRV | 38 ms (RMSSD, Garmin morning HRV, 3-week baseline) |
| Sleep quality | Pittsburgh Sleep Quality Index (PSQI): 9/21 (poor sleep, >5 = abnormal) |
| Comorbidities | No neurological history. No psychoactive medications. Caffeine use: 2 cups/day (unchanged during protocol). |
Protocol Specifications
Compound
Semax (ACTH 4–10 Pro8-Gly9-Pro10 analogue), intranasal
Vial
30 mg lyophilised
Reconstitution
30 mg + 15 mL bacteriostatic water = 2,000 mcg/mL. Transferred to 5 mL nasal spray atomiser.
Spray volume
0.1 mL per actuation = 200 mcg per nostril per spray
Dose per administration
600 mcg total (1 spray × 200 mcg × 3 actuations across both nostrils — alternating L/R/L then L/R/R)
Timing — shift days
Dose 1: 45 min pre-shift start. Dose 2: 6h into shift (mid-shift).
Timing — off days
Single morning dose (600 mcg) for continuity
Total daily dose
1,200 mcg on shift days, 600 mcg off days
Duration
6 weeks continuous, then 2-week washout period
Weekly Tracking — Cognitive & Physiological Metrics
| Timepoint | PCF Score (high-demand shifts) | HRV (RMSSD, ms) | Sleep Onset (avg) | Subjective Observations | Adverse Effects |
|---|---|---|---|---|---|
| Week 0 (Baseline) | 6.8/10 | 38 ms | 42 min | Significant fatigue in final hours of night shifts. Word retrieval delays. Reduced willingness to take on complex cases near end of shift. PSQI: 9/21. | — |
| Week 1 | 6.5/10 | 39 ms | 40 min | Mild tingling in nasal passages (adaptation response). Slight increase in alertness pre-shift described. No significant change to end-of-shift fatigue yet. | Mild nasal tingling (expected — resolved by day 5). No headache. No irritability. |
| Week 2 | 5.4/10 | 42 ms | 35 min | "Sharper" focus during the afternoon fatigue window (hours 8–10 of day shift). Night shift end-of-shift cognition still challenging but noticeably less debilitating. Verbal fluency reported as improved. | None reported. |
| Week 3 | 4.8/10 | 44 ms | 31 min | First week with consistently positive shift-end reports. Word retrieval time described as "normal." Decision prioritisation under simultaneous multiple critical patients felt "less effortful." HRV trend upward. | None reported. |
| Week 4 | 4.2/10 | 46 ms | 28 min | Night shift performance subjectively "back to pre-fatigue levels from 2–3 years ago." Spontaneous reporting of increased motivation to take on additional clinical tasks. Sleep onset time halved versus baseline. | None reported. |
| Week 5 | 3.9/10 | 47 ms | 26 min | Colleague commented unprompted on improved communication clarity during high-stress resuscitation. Error log: 0 near-miss events this week (vs. 2 self-logged near-miss events in pre-protocol baseline month). | None reported. |
| Week 6 (End) | 3.7/10 | 45 ms ▲ +18% | 28 min ▼ −33% | PSQI at end: 6/21 (borderline to normal sleep quality). 6-week protocol completed without interruption. Washout week 1: mild subjective return of late-shift fatigue, which subject describes as "returning to baseline but from a higher floor." | No adverse effects across 6 weeks. No tolerance or diminishing returns observed within the protocol duration. |
−46%
Perceived cognitive fatigue (6.8 → 3.7)
+18%
HRV increase (38 → 45 ms RMSSD)
−33%
Sleep onset time (42 → 28 min avg)
PSQI 9→6
Sleep quality improvement (borderline normal)
Key Observations & Researcher Notes
- Semax's BDNF mechanism is the most likely driver of the cognitive improvement pattern observed. BDNF (brain-derived neurotrophic factor) upregulation supports both synaptic plasticity and GABAergic neurotransmission stabilisation — which directly affects working memory performance and verbal fluency under high cognitive load. The 1–2 week onset before significant PCF changes is consistent with the time required for BDNF-mediated neuroplastic changes.
- HRV improvement (+18%) is clinically relevant as a proxy for autonomic nervous system function. Higher RMSSD correlates with reduced sympathetic dominance and better recovery capacity — important in an occupation with chronic stress exposure. The HRV improvements persisted through week 6 without plateau, suggesting continued adaptation rather than acute stimulant effects.
- Intranasal delivery rationale: Olfactory pathway delivery allows direct CNS access via the cribriform plate, bypassing the blood-brain barrier. This pharmacokinetic advantage makes intranasal peptide delivery uniquely appropriate for centrally-acting compounds like Semax, Selank, and DSIP, where systemic bioavailability would otherwise be negligible.
- Sleep onset time reduction (42 → 28 min) may reflect reduced cortisol/noradrenergic reactivity at sleep initiation, consistent with BDNF's modulation of the hypothalamic-pituitary-adrenal (HPA) axis. This secondary sleep benefit was not the primary protocol target but may represent a clinically meaningful co-benefit for rotating-shift workers.
- No tolerance observed at 6 weeks. This is consistent with the literature on repeated Semax use, where BDNF upregulation appears to be cumulative rather than subject to acute receptor downregulation. Prolonged protocols (beyond 8 weeks) are less studied and should be approached with caution pending further research.
Methodology & Documentation Standards
Data Collection
All case studies use structured daily logging protocols with pre-defined outcome measures established before the protocol begins. Outcome measures are validated scales (VISA-A, VAS, PCF, PSQI) or objective laboratory/imaging data where available.
Anonymisation
Subject data is presented in anonymised, non-identifiable form. Ages are rounded to nearest 5 years, weights to nearest kg, and identifying occupational details are generalised. No combination of data points can be used to identify individual subjects.
Limitations
These are single-subject observational cases, not controlled trials. Confounding variables (diet, sleep, concurrent training changes) are noted where identified but cannot be fully controlled. Results should not be generalised to clinical populations without independent replication.
Compound Purity
All peptides used in documented protocols were sourced from suppliers providing third-party HPLC purity certificates (>98% purity). Reconstitution was performed using pharmaceutical-grade bacteriostatic water with benzyl alcohol. Storage followed strict 2–8°C protocol.
Related Resources
Research Studies
Peer-reviewed literature summaries for the compounds featured in these case studies, organised by peptide and therapeutic area.
Browse Studies →Protocol Calculators
Reconstitution, dosing, and vial duration calculators used to design the protocols documented in these case studies.
Open Calculators →Safety Guidelines
Storage, reconstitution, and adverse event guidance relevant to all compounds covered in these case studies.
View Guidelines →FAQ
Answers to the most common questions about the peptides, protocols, and dosing approaches covered in these case studies.
Read FAQ →